Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409725 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1GAASMN1; SMN2PTGDR2 | |
| SCHEMBL2410961 | 0.84 | CYP1A2 (0.39) | KDM4EALDH1A1GAASMN1; SMN2PTGDR2 | |
| SCHEMBL2410966 | 0.84 | CYP1A2 (0.39) | KDM4EALDH1A1GAASMN1; SMN2PTGDR2 | |
| SCHEMBL2417680 | 0.80 | PTGER1 (0.35) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2417678 | 0.80 | PTGER1 (0.35) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2418759 | 0.77 | KDM4E (0.49) | KDM4EALDH1A1GAASMN1; SMN2PTGDR2 | |
| SCHEMBL2418762 | 0.77 | KDM4E (0.49) | KDM4EALDH1A1GAASMN1; SMN2PTGDR2 | |
| SCHEMBL2412056 | 0.75 | BRD4 (0.32) | — | |
| SCHEMBL2412061 | 0.75 | BRD4 (0.32) | — | |
| SCHEMBL1974258 | 0.73 | GPR119 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | KDM4E 1719/4885ALDH1A1 1420/4885GAA 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.